Global Aspirin Market Size, Share, Opportunities, And Trends By Product (Prescription, OTC), By Application (Cardiovascular Disease, Pain/Fever/Inflammation, Others), By Distribution Channel (Hospital and Retail Pharmacies, Online Channels), And By Geography- Forecasts From 2025 To 2030

The global aspirin market size is estimated to augment at a CAGR of 2.81%, increasing from US$2.507 billion in 2025 to US$2.858 billion by 2030.

Aspirin is also known as acetylsalicylic acid (ASA). The versatility of the chemical is propelling the market growth during the forecast period. Common applications include reducing fever, as a pain reliever, as an anti-inflammatory drug and is also used as a blood thinner. The drug is available worldwide as prescription aspirin and non-prescription or OTC aspirin.

However, due to certain side effects of aspirin, there are concerns that people are rethinking drug uptake without a prescription. This factor might be a restraining factor for market growth during the forecast period. In some cases, for example, aspirin is utilized as an additive in developing specific healthcare products like hydrogels by the multinational company Cardinal Health. Such product formation incorporating aspirin as one of their ingredients also contributes to the market growth in the forecast period. Cardinal Health is a global healthcare service and products company that deals in developing and manufacturing an extensive line of hydrogels for varied end-use applications. These include ECG signaling, defibrillation, electrosurgical, wound care, cosmetics, and other applications. Hydrogel additives include aloe, vitamins A, C, and E, menthol, aspirin, camphor, lidocaine, green tea extract, and fragrances including cinnamon, essential oils, cucumber, and rose.

The growing API, i.e., active pharmaceutical ingredient industry, will further contribute to propelling the market growth of acetylsalicylic acid as an active ingredient in drug formulations. From the APAC region, China is estimated to hold a significant market share in the global API industry. The augmenting retail industry and booming e-commerce sales are propagating market growth during the forecast period. 

What are the Global Asprin Market drivers?

• The presence of companies offering acetylsalicylic acid products is propelling market growth during the forecast period

Bayer Aspirin has been an essential medicine for over 100 years. It helps alleviate pain and prevent cardiovascular events and has stood the test of time. In the form of a brand, Aspirin™ is among the highly trusted products by a range of customers worldwide compared to any other over-the-counter medicine for reducing pain. The World Health Organization lists aspirin as an essential medication based on its pain relief and anti-platelet effects.

The company's product portfolio includes Aspirin and Aspirin Cardio as its products. Aspirin™ falls under the category of consumer health and pharmaceuticals. Aspirin Cardio is designed explicitly for cardiology applications. With the growing number of cardiovascular diseases, aspirin is prescribed for blood thinning applications. A physician may prescribe a low-dose aspirin for the prevention of blood clots. This further aids in the reduction of stroke and heart attack risks. A patient who underwent surgery to treat clogged arteries, including a bypass surgery or surgery for a stenting procedure, is mostly prescribed aspirin in the form of blood thinners for preventing blood clots. On the other hand, aspirin for consumer health includes the following applications: headache, body pain, muscle pain, and fever.

Par Pharmaceutical, a generic pharmaceutical company, offers quality medicines to a range of customers. These drug products are of high quality and cost-effective, achieved through excellence in innovation, development, manufacturing, and commercialization. The company manufactures aspirin & extended-release dipyridamole capsules as one of the crucial products in its generic product portfolio.

Allegiant Health manufactures and markets over-the-counter drugs and nutritional supplements. The company was formed due to a spin-off from a division of A&Z Pharmaceutical Inc., a leading US manufacturer and markets OTC drugs. 

Under its analgesics section, the company uses aspirin as an active ingredient in various product variants. The company's aspirin products include chewable aspirin (orange flavor), chewable aspirin (cherry flavor), enteric-coated aspirin, and regular-strength aspirin therapy. 

Nanjing Pharmaceutical Factory Co., Ltd. is an extensive and integrated API, finished dosage, and fine chemicals manufacturer with robust research and development capabilities. From the finished dosages section, the company manufactures aspirin enteric-coated tablets. From the APIs section, the company manufactures aspirin for non-steroidal anti-inflammatory drugs and anti-platelet aggregation drugs category. The company’s API manufacturing site spans an area of 120,000 square meters consisting of six dedicated and multi-purpose workshops coupled with abundant land for expansion. The production and quality systems are operated as per the cGMP requirements. The API commodities supplied worldwide include highly regulated markets, the United States, and the European Union. The company’s finished dosages plant spans an area of 70,000 square meters and deals in the production of tablets, capsules, and granules, in addition to the production of small-volume injections and lyophilized powder for injections. All the products are available at a competitive price for the customers.

• The growing demand for branded generics will continue to boost market growth during the forecast period

The global branded generics market is projected to grow in the forecast period with the marketing approval by the FDA for several generic drug products in 2024. Hence, this will continue to strengthen the market growth during the forecast period. Generic drugs are comparatively cheaper than branded products. Hence, poorer countries where people cannot afford costly medical treatments cannot buy branded medicines that come under treatment costs post-treatment.

Thus, the generic versions of aspirin will continue to soar the market growth in the forecast period. As per the USFDA, generic medicines are around 80 to 85% cheaper than branded versions. Therefore, these medicines play an important role in offering cost-effective health care, further contributing to surging their use with time worldwide.

As per the prescription audit statistics, generic medicines account for more than 80% share of the total medicines prescribed in the United States, the United Kingdom, China, and Australia. In India, although generic medicines are exported in large volumes to other countries, doctors prescribe less than 50% of these medicines. One of the primary reasons is the lack of confidence in the quality of unbranded generic medicine. Hence, branded generics are gaining momentum, further fueling the market for branded aspirin in the forecast period. Additionally, generics consumption in India is mostly available in branded generics only.

• The prevalence of headaches worldwide will fuel the demand for analgesics, augmenting the market growth during the forecast period

According to the World Health Organization, headaches are the most common nervous system disorders. Most adults suffer from headaches frequently. One of the major reasons can be attributed to the changing living conditions where there is high competition among people in every part of their life, be it child upbringing, choosing a career, and efforts to excel in every field they choose. Hence, this has created more tension, thus raising the stress level. The demand for analgesics is gaining momentum with the evolving consumer lifestyle, further offering strong market growth prospects during the forecast period for immediate pain relief. One of the most consumed drugs containing aspirin as an active ingredient is disprin.

The product is now available in different new variants, including Disprin Direct. Different types of headaches, as listed by the WHO, include migraine, tension-type headaches, cluster headaches, and medication overuse headaches. Additionally, as per NIH information, around 1 to 2% of individuals worldwide suffer from chronic migraine. Around 2.5% of people suffering from episodic migraine progress to chronic migraine. Hence, such events will contribute to the surging market growth with the soaring demand for pain relievers in the forecast period. One can find aspirin in three different formats: standard tablets to swallow with water, soluble tablets that can be dissolved in a glass of water, and enteric-coated tablets; consumption is done by swallowing whole with water. 

Global Aspirin Market Scope:

Report Metric	Details
Global Aspirin Market Size in 2025	US$2.507 billion
Global Aspirin Market Size in 2030	US$2.858 billion
Growth Rate	CAGR of 2.81%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Product Application Distribution Channel Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in Global Aspirin Market	Bayer AG Hebei Jingye Chemical Co., Ltd. JQC (Huayin) Pharmaceutical Co., Ltd. Perrigo Company plc L.N.K. International Inc.
Customization Scope	Free report customization with purchase

 

The Global Aspirin Market is analyzed into the following segments:

• By Product
  • Prescription
  • OTC

• By Application
  • Cardiovascular Disease
  • Pain/Fever/Inflammation
  • Others

• By Distribution Channel
  • Hospital and Retail Pharmacies
  • Online Channels

• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • Spain
    • United Kingdom
    • France
    • Others
  • Middle East and Africa
    • UAE
    • Israel
    • Saudi Arabia
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Taiwan
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key Benefits for the Stakeholders

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Process

2.3. Data Validation

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS6

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Supplier

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. GLOBAL ASPIRIN MARKET BY PRODUCT

5.1. Introduction

5.2. Prescription

5.3. OTC

6. GLOBAL ASPIRIN MARKET BY APPLICATION

6.1. Introduction

6.2. Cardiovascular Disease

6.3. Pain/Fever/Inflammation

6.4. Others

7. GLOBAL ASPIRIN MARKET BY DISTRIBUTION CHANNEL

7.1. Introduction

7.2. Hospital and Retail Pharmacies

7.3. Online Channels

8. GLOBAL ASPIRIN MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Product 

8.2.2. By Application

8.2.3. Distribution Channel 

8.2.4. By Country

8.2.4.1. United States

8.2.4.2. Canada

8.2.4.3. Mexico

8.3. South America

8.3.1. By Product 

8.3.2. By Application

8.3.3. Distribution Channel 

8.3.4. By Country

8.3.4.1. Brazil

8.3.4.2. Argentina

8.3.4.3. Others

8.4. Europe

8.4.1. By Product 

8.4.2. By Application

8.4.3. Distribution Channel 

8.4.4. By Country

8.4.4.1. Germany

8.4.4.2. Spain

8.4.4.3. United Kingdom

8.4.4.4. France

8.4.4.5. Others

8.5. Middle East and Africa

8.5.1. By Product 

8.5.2. By Application

8.5.3. Distribution Channel 

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.2. South Africa

8.5.4.3. Others

8.6. Asia Pacific

8.6.1. By Product 

8.6.2. By Application

8.6.3. Distribution Channel 

8.6.4. By Country

8.6.4.1. China

8.6.4.2. Japan

8.6.4.3. Australia

8.6.4.4. India

8.6.4.5. South Korea

8.6.4.6. Thailand

8.6.4.7. Taiwan 

8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES 

10.1. Bayer AG

10.2. Hebei Jingye Chemical Co., Ltd. 

10.3. JQC (Huayin) Pharmaceutical Co., Ltd.

10.4. Perrigo Company plc

10.5. L.N.K. International Inc.

10.6. Thermo Fisher Scientefic

10.7. Taj Pharmaceuticals Limited

10.8. Advance Pharmaceutical Inc.

10.9. Allegiant Health

10.10. KEM Pharma LLC

Bayer AG

Hebei Jingye Chemical Co., Ltd. 

JQC (Huayin) Pharmaceutical Co., Ltd.

Perrigo Company plc

L.N.K. International Inc.

Thermo Fisher Scientefic

Taj Pharmaceuticals Limited

Advance Pharmaceutical Inc.

Allegiant Health

KEM Pharma LLC